文献速递胸部肿瘤

ERBB2激活突变非小细胞肺癌的分子特征与临床结局:日本全国真实世界队列

Molecular characteristics and clinical outcomes of ERBB2-activating mutation-positive non-small cell lung cancer: A Japanese nationwide real-world cohort.
PubMed 文献 · Eur J Cancer · 2026-09-29

该回顾性队列基于日本全国癌症基因组与先进治疗中心数据库,纳入319例ERBB2激活突变非小细胞肺癌患者,分析分子特征与临床结局。结果显示74%为经典TKD框内插入,26%为非经典变异;仅5.6%存在共驱动变异且主要见于非经典变异。288例有生存数据者中27%接受T-DXd,时依暴露与死亡风险降低相关(调整HR 0.63,95%CI 0.39-1.01,P=0.057)。

要点

  • ERBB2激活突变NSCLC中74%为经典TKD框内插入,26%为非经典变异。
  • 共驱动变异仅见于5.6%患者,且几乎限于非经典变异。
  • T-DXd暴露与死亡风险降低相关,但95%CI跨1、P=0.057。

核心结论

  • ERBB2突变NSCLC呈现显著分子异质性,经典TKD框内插入共驱动变异频率低。
  • 在ERBB2激活突变患者中,T-DXd暴露与总生存改善相关。

研究设计与样本

  • 回顾性分析日本全国癌症基因组与先进治疗中心数据库的常规临床全面基因组检测数据。
  • 共纳入319例ERBB2激活突变NSCLC患者,其中288例有生存数据。

主要发现

  • 74%患者携带经典TKD框内插入,26%携带非经典变异(TKD错义8%、跨膜/近膜域10%、ECD突变8%)。
  • 共驱动致癌变异仅18例(5.6%),主要见于非经典变异,经典TKD框内插入中未检出。
  • 非经典变异中TKD错义和ECD突变与肿瘤突变负荷升高相关。
  • 288例有生存数据者中78例(27%)临床过程中接受T-DXd。
  • 排除在全面基因组检测前已开始T-DXd者后,时依T-DXd暴露与死亡风险降低相关(调整HR 0.63,95%CI 0.39-1.01,P=0.057)。

临床怎么用

  • 对ERBB2激活突变NSCLC应区分经典TKD框内插入与非经典变异以评估共驱动变异风险。
  • 非经典变异(尤其TKD错义和ECD突变)可考虑关注肿瘤突变负荷。
  • T-DXd在本真实世界队列中与生存改善相关,但证据强度受限于置信区间跨1。

局限性

  • 为回顾性真实世界分析,非随机对照设计。
  • T-DXd与生存关联的95%CI上限为1.01且P=0.057,未达常规统计学显著。
  • 生存分析排除检测前已开始T-DXd者,可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Erb-b2 receptor tyrosine kinase 2 (ERBB2)-activating mutations are well-documented oncogenic drivers in non-small cell lung cancer (NSCLC), occurring in approximately 1-4% of cases. These alterations include a heterogeneous spectrum of variant subtypes; however, the clinicogenomic characteristics and clinical significance of the individual variants have yet to be elucidated. METHODS: We searched the nationwide Center for Cancer Genomics and Advanced Therapeutics database, which integrates comprehensive genome profiling data generated in routine clinical practice across Japan, to investigate the molecular landscape and clinical outcomes of patients with ERBB2-mutated NSCLC. RESULTS: A total of 319 patients with ERBB2-activating mutations were included in this retrospective analysis. Although 74% of the patients harbored canonical tyrosine kinase domain (TKD) in-frame insertions, 26% carried noncanonical variants, including TKD missense (8%), transmembrane/juxtamembrane domain (10%), and extracellular domain (ECD) mutations (8%). Co-occurring oncogenic driver alterations were identified in only 18 cases (5.6%) and were largely restricted to noncanonical variants, whereas no co-occurring driver alterations were detected among patients with TKD in-frame mutations. Noncanonical variants-TKD missense and ECD mutations in particular-were associated with an increased tumor mutational burden. Among 288 patients with available survival data, 78 (27%) received trastuzumab deruxtecan (T-DXd) during their clinical course. After excluding patients who had started treatment with T-DXd before undergoing comprehensive genome profiling testing, time-dependent T-DXd exposure was associated with a reduced risk of death (adjusted hazard ratio, 0.63; 95% confidence interval, 0.39-1.01; P = 0.057). CONCLUSIONS: ERBB2-mutated NSCLC exhibited substantial molecular heterogeneity, with canonical TKD in-frame insertions characterized by a low frequency of co-occurring oncogenic driver alterations. Among patients harboring ERBB2-activating mutations, exposure to T-DXd was associated with improved overall survival.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yamashita M, Ninomiya K, Tomida S, et al. Molecular characteristics and clinical outcomes of ERBB2-activating mutation-positive non-small cell lung cancer: A Japanese nationwide real-world cohort. Eur J Cancer. 2026. PMID: 42826440. doi:10.1016/j.ejca.2026.117443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。